Cancer cells die without sugar
More than half of all cancer cases show a significantly increased sugar metabolism. This means that tumors continue to multiply unhindered, form metastases and remain resistant to radiation and chemotherapy.
A recent study by the Berlin Charité - Universitätsmedizin and the Max Delbrück Center for Molecular Medicine again proves that cancer cells have an increased activity in sugar metabolism. If the scientists inhibited the cell's sugar metabolism, they died. As early as 1924, the German biochemist and later Nobel Prize winner Otto Heinrich Warburg was able to identify a changed metabolism in carcinomas.
Cells require sufficient energy to maintain cell function and cell division. A cancer cell has two different metabolic pathways for energy generation - either combustion or fermentation. Switching the energy production from combustion to fermentation and the associated formation of lactic acid as a protective shield leads to the development of resistance to radiation and chemotherapy. Studies by the Institute of Physiology and Pathophysiology at the University of Mainz in 2011 showed that the intensity of lactic acid accumulation in cancer cells is closely related to the radiation and immune resistance of tumors, the formation of metastases and the overall survival rate of cancer patients.
The TKTL1 metabolism is an additional way through which cells can convert glucose (blood sugar) into energy and was created as a protective mechanism in the course of evolution. Nerve cells are preserved longer, genetic information is passed on in a stable manner and cells are protected from programmed cell death (apoptosis). In 1995 Dr. Johannes Coy the gene TKTL1 (Transketolase-like-1), which carries every cell within it to switch to this metabolic pathway. According to his findings, tumor cells are activated with the help of TKTL1 and set in motion a protective mechanism via their altered sugar metabolism, which protects them from apoptosis and makes them resistant to chemotherapy and radiation therapy.
Around every second cancer patient has TKTL1-positive cells that are very likely to prevent the success of the treatment and further promote cancer development. Therefore, when diagnosing cancer, a blood test should first be used to determine whether there are TKTL1-positive cells, i.e. resistant cell structures.
Since this protective mechanism cannot yet be stopped with medication, TAVARLIN AG has developed Coy Complete as a drinking food so that tumor cells become more sensitive to conventional cancer therapies again. The patented recipe corresponds to a ketogenic, i.e. strictly low-carbohydrate diet, which should be used in TKTL1-positive findings to inhibit TKTL1 metabolism. It is a fully balanced, sugar-free drinking food that switches the body to a ketogenic metabolism, so that tumor cells are withheld from the energy supplier glucose and remain sensitive to the accompanying cancer therapy - without fasting. Additional nutrients, enriched with additional natural substances, provide additional support. Patients with a diagnosed cancer and proven TKTL1 metabolism are given the opportunity to positively influence the success of their surgery, radiation and chemotherapy through their own, optimized diet. (pm)